Grufity logo
Grufity logo
VOR

VOR - Vor Biopharma Inc. Stock Price, Fair Value and News

$21.16-0.64 (-2.94%)
Market Closed as of 31 Jul 2026, 04:00 pm ET

Price Targets

VOR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VOR Price Action

Last 7 days

9.9%

Last 30 days

15.1%

Last 90 days

52.8%

Trailing 12 Months

-48.9%

VOR RSI Chart

VOR Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

VOR Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

-1.3

Price/Free Cashflow

-7.61

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

VOR Fundamentals

VOR Earnings

Earnings (TTM)

-883.1M

Earnings Growth (Yr)

-575.94%

Earnings Growth (Qtr)

-112.75%

VOR Profitability

Return on Equity

587.06%

Return on Assets

-174.26%

Free Cashflow Yield

-13.14%

VOR Investor Care

Shares Dilution (1Y)

768.20%

Diluted EPS (TTM)

-70.36

Revenue & Growth

How Vor Biopharma Inc. generates revenue and covers its expenses, based on the latest reported earnings.

About Vor Biopharma Inc.

VOR
Vor Biopharma Inc., a clinical-stage company, engages in the development of engineered hematopoietic stem cell (eHSC) therapies for cancer patients. The company is developing lead product, tremtelectogene empogeditemcel (trem-cel), formerly VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. It also offers Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, currently under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system, currently under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system, made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, currently under preclinical studies for the treatment of AML. Vor Biopharma Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEvorbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES133

Vor Biopharma Inc. Frequently Asked Questions

VOR is the stock ticker symbol of Vor Biopharma Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jul 31 2026, market cap of Vor Biopharma Inc. is 1.15 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.